Today’s big health story is the National Institute of Clinical Excellence’s (NICE) final decision to restrict the prescribing of drugs for Alzheimer’s disease. Basically, NICE has said that there’s not enough evidence of cost-effectiveness to support the use of such drugs in individuals in the early stages of this condition. Patient groups, including the Alzheimer’s [...]

